Fig. 1
From: In vivo pre-activation of monocytes in patients with axial spondyloarthritis
Elevated percentage of classic monocytes in patients with axial spondyloarthritis (axSpA). a The percentage of classic CD14++CD16− (M1), intermediate CD14++CD16+ (M2), and non-classic CD14+CD16+ (M3) monocytes was determined by fluorescence-activated cell sorting in whole blood of controls, patients with axSpA, and patients with rheumatoid arthritis (RA). The percentage of classic, intermediate, and non-classic monocytes was determined among monocytes which were gated according to forward (FSC) and side (SSC) scatter (R1) and HLA-DR expression (R2). b The percentage of classic, intermediate, and non-classic monocytes (individual measurements and median) is shown from measurements in 12 controls (C), 20 patients with axSpA (SpA), and 12 patients with RA (RA). *P < 0.05, **P < 0.01 (Kruskal-Wallis test and Dunn’s post test). c The percentage of the respective populations in axSpA patients separated into patients under conventional treatment (SpA CT) (n = 12) and patients receiving biologics (i.e., tumor necrosis factor inhibitors) (SpA BT) (n = 8) compared with controls (c). *P < 0.05, **P < 0.01 (Kruskal-Wallis test and Dunn’s post test). FITC fluorescein isothiocyanate